Institute for Evolutionary Biology and Environmental Sciences, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Curr Biol. 2012 Sep 11;22(17):R762-71. doi: 10.1016/j.cub.2012.06.065.
Cancer initiation, progression, and the emergence of therapeutic resistance are evolutionary phenomena of clonal somatic cell populations. Studies in microbial experimental evolution and the theoretical work inspired by such studies are yielding deep insights into the evolutionary dynamics of clonal populations, yet there has been little explicit consideration of the relevance of this rapidly growing field to cancer biology. Here, we examine how the understanding of mutation, selection, and spatial structure in clonal populations that is emerging from experimental evolution may be applicable to cancer. Along the way, we discuss some significant ways in which cancer differs from the model systems used in experimental evolution. Despite these differences, we argue that enhanced prediction and control of cancer may be possible using ideas developed in the context of experimental evolution, and we point out some prospects for future research at the interface between these traditionally separate areas.
癌症的发生、进展以及治疗耐药性的出现是克隆体细胞群体的进化现象。微生物实验进化研究及其所启发的理论工作正在深入了解克隆群体的进化动态,但对于这一快速发展领域与癌症生物学的相关性,人们关注甚少。在这里,我们探讨了从实验进化中涌现出的关于克隆群体中突变、选择和空间结构的理解如何适用于癌症。在此过程中,我们讨论了癌症与实验进化中使用的模型系统在一些重要方面的差异。尽管存在这些差异,我们认为,在实验进化的背景下发展起来的观点可以用于增强对癌症的预测和控制,并且我们指出了这两个传统上相互独立的领域之间的一些未来研究前景。